Clinical trials: Cutaneous Melanoma, Stage II
Clinical Stage IV Cutaneous Melanoma AJCC v8, Locally Advanced Melanoma
Testing Dabrafenib and Trametinib With or Without Hydroxychloroquine in Stage IIIC or IV BRAF V600E/K Melanoma
This phase II trial investigates how well adding hydroxychloroquine to the standard treatment of dabrafenib and trametinib works to overcome resistance and delay disease progression in treating patients with stage IIIC or IV BRAF…
- Conditions
- Clinical Stage IV Cutaneous Melanoma AJCC v8, Locally Advanced Melanoma, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8
- Trial name
- NCT04527549
- Testing
- Dabrafenib mesylate, Hydroxychloroquine, Trametinib dimethyl sulfoxide
- Where
- 199 sites in United States
- Volunteers
- 5 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Melanoma, Stage II, Melanoma Stage III
Assessment of PK Similarity of FYB206 in Comparison With Keytruda in Resected Stage II or III Melanoma Patients
Melanoma is a kind of skin cancer that starts in the melanocytes. Melanocytes are cells that make the pigment that gives skin its colour. 'Resected' means the melanoma has been completely removed with surgery.
- Trial name
- Dahlia (NCT06551064)
- Testing
- FYB206, Keytruda
- Where
- 17 sites in Bosnia and Herzegovina, Bulgaria and 9 more
- Volunteers
- 96 people
- Sponsor
- Formycon AG
Melanoma (Skin)
Combination Chemotherapy, Total-Body Irradiation, Peripheral Stem Cell Transplantation, and Lymphocyte Infusion in Treating Patients With Stage IV Melanoma
RATIONALE: Drugs used in chemotherapy such as fludarabine use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00006233
- Testing
- therapeutic allogeneic lymphocytes, cyclosporine, fludarabine phosphate
- Where
- United States
- Sponsor
- Fred Hutchinson Cancer Center
Advanced Solid Tumor
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
This study will evaluate the safety, efficacy, optimal dose, and pharmacokinetics (PK) of BNT326 as monotherapy (Part 1) and as combination treatment with immunotherapeutic agents (Part 2) in participants with histologically or…
- Trial name
- NCT07070232
- Testing
- BNT326, Pumitamig, Itraconazole
- Where
- 77 sites in United States, Australia and 7 more
- Volunteers
- 1,438 people
- Sponsor
- BioNTech SE
Melanoma
A Study of YM155 Plus Docetaxel in Subjects With Stage III (Unresectable) or Stage IV Melanoma
The purpose of the study is to evaluate survival, response rate, safety and tolerability of YM155 given in combination with docetaxel in subjects with Stage III (unresectable) and Stage IV melanoma.
- Trial name
- NCT01009775
- Testing
- YM155, Docetaxel
- Where
- 13 sites in United States, Canada
- Volunteers
- 64 people
- Sponsor
- Astellas Pharma Inc
Melanoma (Skin)
Vaccine Therapy in Treating Patients With Metastatic Melanoma
RATIONALE: Vaccines made from peptide 946 may make the body build an immune response to kill tumor cells. Combining these vaccines with proteins from the tetanus vaccine, and/or with either QS21 or Montanide ISA-51 may be an…
- Trial name
- NCT00003224
- Testing
- QS21, IFA (incomplete Freund's adjuvant), p946
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- University of Virginia
Malignant Melanoma
Phase II Trial of Ontak With Metastatic Melanoma
The purpose of this study is to determine whether ONTAK is an effective treatment in patients with Stage IV Melanoma
- Trial name
- NCT00299689
- Testing
- Denileukin diftitox
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- James Graham Brown Cancer Center
Clinical Stage 0 Cutaneous Melanoma AJCC v8, Clinical Stage I Cutaneous Melanoma AJCC v8
PRAME Immunohistochemistry-Guided Slow Mohs Micrographic Surgery for the Treatment of Stage 0 to IIc Cutaneous Melanoma
This clinical trial tests the addition of preferentially expressed antigen in melanoma (PRAME) immunohistochemical (IHC) staining to standard slow Mohs micrographic surgery (SMMS) for guiding tissue removal in patients with stage…
- Conditions
- Clinical Stage 0 Cutaneous Melanoma AJCC v8, Clinical Stage I Cutaneous Melanoma AJCC v8, Clinical Stage II Cutaneous Melanoma AJCC v8
- Trial name
- NCT07258446
- Testing
- Immunohistochemistry Staining Method, Mohs Surgery
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- University of California, Davis
Melanoma
Cytokine-induced Killer Study for Patients With Stage II Melanoma
For investigators' current experimental clinical trial, patients are given 4 injections of ipilimumab, given 3 weeks apart x 4 injections with or without cytokine-induced killer therapy.
- Trial name
- NCT02498756
- Testing
- Cytokine-induced killer cells, Ipilimumab
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- The First People's Hospital of Changzhou
Hematopoietic and Lymphoid Cell Neoplasm, Locally Advanced Malignant Solid Neoplasm
Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer
This phase I/II trial studies the side effects and the best dose of uprosertib when given together with dabrafenib and trametinib and to see how well they work in treating patients with stage IIIC-IV cancer.
- Conditions
- Hematopoietic and Lymphoid Cell Neoplasm, Locally Advanced Malignant Solid Neoplasm, Locally Advanced Melanoma, Metastatic Malignant Solid Neoplasm
- Trial name
- NCT01902173
- Testing
- Biopsy, Biospecimen Collection, Computed Tomography
- Where
- 16 sites in United States
- Volunteers
- 27 people
- Sponsor
- National Cancer Institute (NCI)
Melanoma
Neoadjuvant Dabrafenib + Trametinib for AJCC Stage IIIB-C BRAF V600 Mutation Positive Melanoma
This is an open label, single centre, phase II study of neoadjuvant drug treatment with dabrafenib + trametinib in patients with resectable American Joint Committee on Cancer (AJCC) Stage IIIB-C BRAF V600 mutation positive…
- Trial name
- Neo Combi (NCT01972347)
- Testing
- Dabrafenib, Trametinib
- Where
- Australia
- Volunteers
- 35 people
- Sponsor
- Melanoma Institute Australia
Cancer
Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor
RATIONALE: When irradiated lymphocytes from a donor are infused into the patient they may help the patient's immune system kill cancer cells.
- Trial name
- NCT00161187
- Testing
- therapeutic allogeneic lymphocytes
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- University of Medicine and Dentistry of New Jersey
Acral Lentiginous Malignant Melanoma, Ciliary Body and Choroid Melanoma, Medium/Large Size
AZD2171 in Treating Patients With Recurrent or Stage IV Melanoma
This phase II trial is studying how well AZD2171 works in treating patients with recurrent or stage IV melanoma. AZD2171 may stop the growth of tumor cells by blocking blood flow to the tumor and by blocking some of the enzymes…
- Conditions
- Acral Lentiginous Malignant Melanoma, Ciliary Body and Choroid Melanoma, Medium/Large Size, Ciliary Body and Choroid Melanoma, Small Size, Extraocular Extension Melanoma
- Trial name
- NCT00243061
- Testing
- cediranib maleate
- Where
- Canada
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Melanoma, Stage IV Melanoma
Vaccine Therapy in Treating Patients With Metastatic Melanoma
Vaccines may make the body build an immune response to kill tumor cells. Injecting a vaccine directly into a tumor may cause a stronger immune response and kill more tumor cells.
- Trial name
- NCT00087373
- Testing
- recombinant fowlpox-TRICOM vaccine, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- National Cancer Institute (NCI)
Malignant Melanoma Stage III, Malignant Melanoma Stage IV
Autologous TriMix-DC Therapeutic Vaccine in Combination With Ipilimumab in Patients With Previously Treated Unresectable Stage III or IV Melanoma
The CTLA-4 blocking monoclonal antibody ipilimumab (MDX-010, BMS-734016), has demonstrated anti-tumor activity in a subgroup of patients with Stage III (unresectable) or Stage IV melanoma (measurable per modified WHO criteria)…
- Trial name
- TriMix-Ipi (NCT01302496)
- Testing
- TriMix-DC and ipilimumab
- Where
- Belgium
- Volunteers
- 39 people
- Sponsor
- Bart Neyns
Melanoma (Skin)
Laboratory-Treated Autologous Lymphocytes and Aldesleukin After Cyclophosphamide and Fludarabine in Treating Patients With Metastatic Melanoma
RATIONALE: Treating lymphocytes in the laboratory may help the lymphocytes kill more tumor cells when they are put back in the body. Aldesleukin may stimulate the lymphocytes to kill tumor cells.
- Trial name
- NCT00863330
- Testing
- Tumor Infiltrating Lymphocytes (TIL)
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Wake Forest University Health Sciences
Clinical Stage 0 Cutaneous Melanoma AJCC v8, Clinical Stage I Cutaneous Melanoma AJCC v8
Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer
This trial studies the role of the gut microbiome and effectiveness of a fecal transplant on medication-induced gastrointestinal (GI) complications in patients with melanoma or genitourinary cancer.
- Conditions
- Clinical Stage 0 Cutaneous Melanoma AJCC v8, Clinical Stage I Cutaneous Melanoma AJCC v8, Clinical Stage IA Cutaneous Melanoma AJCC v8, Clinical Stage IB Cutaneous Melanoma AJCC v8
- Trial name
- NCT03819296
- Testing
- Best Practice, Biospecimen Collection, Endoscopic Procedure
- Where
- United States
- Volunteers
- 800 people
- Sponsor
- M.D. Anderson Cancer Center
Malignant Melanoma
Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E
This is an open-label, multicenter, single-agent, phase II study of continuous oral Zelboraf (vemurafenib) in participants with locally-advanced, unresectable, stage IIIc or metastatic melanoma and activating exon 15 BRAF…
- Trial name
- NCT01586195
- Testing
- Vemurafenib
- Where
- 15 sites in United States
- Volunteers
- 31 people
- Sponsor
- Genentech, Inc.
Stage IV Melanoma
Aldesleukin With or Without Vaccine Therapy in Treating Patients With Stage IV Melanoma
RATIONALE: Aldesleukin may stimulate the white blood cells to kill tumor cells. Vaccines may help the body build an effective immune response to kill tumor cells.
- Trial name
- NCT00726739
- Testing
- aldesleukin, allogeneic large multivalent immunogen vaccine
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Melanoma
A Study of Recombinant Vaccinia Virus to Treat Malignant Melanoma
The purpose of this research study is to find out whether JX-594 (Pexa-Vec) is safe and effective for treating surgically unresectable malignant melanoma.
- Trial name
- NCT00429312
- Testing
- JX-594
- Where
- 3 sites in United States
- Volunteers
- 10 people
- Sponsor
- Jennerex Biotherapeutics